Recent Updates
Recently added Catalysts

AZD3839

Phase 1

Alzheimer's Disease | Small molecule | Neurology |AstraZeneca PLC|Last Updated: Apr 6, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment72

FDA Designations

No designations recorded

Clinical trial landscape

AZD3839 · 1 trial · 5 indications

Phase 1 1
NCT01348737Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy VolunteersAlzheimer's Disease
COMPLETED72 Analytics
PHASE1COMPLETED
Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers
Alzheimer's Disease
NCT0134873772
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Adverse Event as a measure of safety and tolerability of AZD3839 (Part 1)
Part 1 - AEs will be collected from admission to the study centre (Visit 2, Day-1) until the follow-up visit (Visit 3) approximately 15 days
Number of Adverse Events as a measure of Safety and tolerability of AZD3839 (Part 2)
Part 2 - AEs will be collected from admission to the study centre (Visit 2, Day-1) until the follow-up visit (Visit 4) approximately 20 days

Secondary Endpoints

Time at which maximum concentration occurs in AZD3839 (Part 1)
pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the administration of the investigational product, as well as on Day 4 and at the follow-up visit (Visit 3)
Maximum observed concentration of AZD3839 in plasma (Part 1)
Part 1 - pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the administration of the investigational product, as well as on Day 4 and at the follow-up visit (Visit 3)
Time at which maximum concentration occurs in AZD3839 (Part 2)
Part 2 - at pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the Administration. May be taken at the follow-up visit (Visit 4)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
AZD3839EXPERIMENTALOral Treatment
AZD3839 PlaceboPLACEBO_COMPARATOROral Treatment

Interventions

NameTypeDescription
AZD3839DRUGSingle Oral Dose
AZD3839 PlaceboDRUGSingle Oral Dose
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male and female volunteers of non-childbearing potential aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture * Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weigh between 50 kg and 100 kg (inclusive) * Cre...

Countries:United Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Alzheimer's Disease 66 trials

Top 20 of 24 competitors

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY9PHASE3KarXT, KarX-EC
Eli Lilly and CompanyLLY12PHASE3Donanemab, Dexamethasone
Biogen Inc.BIIB2PHASE3Lecanemab
Annovis Bio IncANVS1PHASE3buntanetap/posiphen
ACADIA Pharmaceuticals Inc.ACAD2PHASE3ACP-204
Novartis AG Sponsored ADRNVS2PHASE2VHB937
GSK plc Sponsored ADRGSK2PHASE2GSK4527226
Cognition Therapeutics, Inc.CGTX2PHASE2CT1812
Johnson & JohnsonJNJ1PHASE2JNJ-64042056
Merck & Co., Inc.MRK1PHASE2MK-2214
Lantheus Holdings IncLNTH2PHASE3Nilotinib BE
Acumen Pharmaceuticals, Inc.ABOS1PHASE2sabirnetug
Aclaris Therapeutics, Inc.ACRS1PHASE2ATI-045
IGC Pharma, Inc.IGC1PHASE2IGC-AD1-Active
Alnylam Pharmaceuticals, IncALNY2PHASE1ALN-5288
Arrowhead Pharmaceuticals, Inc.ARWR1PHASE1ARO-MAPT
AC Immune SAACIU2PHASE1ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, ACI-24.060 at Dose A in Study Part 2
Denali Therapeutics Inc.DNLI1PHASE1DNL628
Alzamend Neuro, Inc.ALZN1PHASE1ALZN002
Voyager Therapeutics, Inc.VYGR1PHASE1VY7523
Unlock Competitive Intelligence

Frequently asked questions about AZD3839

What is AZD3839 used for?

AZD3839 is an investigational small molecule being developed for Alzheimer's Disease. It is in Phase 1 clinical development and has been studied in a completed trial in healthy volunteers to assess safety, tolerability, and blood concentrations. AZD3839 is not approved and remains in clinical development.

Who makes AZD3839?

AZD3839 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker AZN. The drug is an investigational small molecule in Phase 1 clinical development for Alzheimer's Disease.

What phase is AZD3839 in?

AZD3839 is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy volunteers, and no active trials are currently listed. The drug is investigational and has not been approved for any use.

What clinical trials is AZD3839 in?

AZD3839 has one completed clinical trial, NCT01348737, titled "Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers." This Phase 1, randomized, double-blind, placebo-controlled study enrolled 72 participants in the United Kingdom.

Is AZD3839 the same as another drug?

AZD3839 is the drug name used in clinical development by AstraZeneca. No alternative names have been reported for this investigational small molecule being studied for Alzheimer's Disease.